Alphabetical list:
A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9
News: November 29, 2009
Rituximab May Offer Hope To Severe Graves' Eye Disease Patients
November 29, 2009There may be hope for patients with severe Graves' eye disease in the form of treatment with the drug rituximab.
This news comes from U-M Kellogg Eye Center who's oculoplastics specialist Raymond S. Douglas, M.D., Ph.D. reports on the potential of the drug in the online October issue of Ophthalmology.
Graves' eye disease is an autoimmune disease that causes inflammation and fatty deposits in the eye muscles and connective tissue surrounding the eye.
Douglas reports on the progress of six patients (four women, two men) who had not responded to treatment using systemic corticosteroids. The patients were then treated with rituximab. All patients responded within 2 months with the clinical activity score (CAS) improving from5.5±0.8 to 1.3±0.5. The eye disease remained quiescent in all with the positive results being sustained at 4-6 months after treatment.
Vision improved bilaterally in all 4 patients with dysthyroid optic neuropathy (DON). Proptosis remained stable (Hertel measurement, 24±3.7 mm before therapy and 23.6±3.7 mm after therapy; P = 0.17).
"These patients had already received the maximum level of steroid treatment," says Douglas. "Treatment with rituximab calmed inflammation, stopped progression of the disease, and saved the patients from having to undergo surgery."
Graves' disease (also known as thyroid eye disease) is an autoimmune condition in which white blood cells attack the thyroid gland which responds by secreting an excess amount of thyroid hormone. The hypermetabolic state is characterized by fast pulse/heartbeat, palpitations, profuse sweating, high blood pressure, irritability, fatigue, weight loss, heat intolerance, and loss of hair and alterations in hair quality.
Rituximab has been used to treat patients with other autoimmune diseases, including rheumatoid arthritis and in non-Hodgkin's B-cell lymphoma. The drug works by depleting B cells - the body's normal antibody-producing cells - that appear to go awry in autoimmune diseases.
"Treatment of the inflammatory component of Graves' eye disease has not advanced appreciably over several decades," says Douglas. High-dose steroids, sometimes in combination with orbital radiation, are still the first line treatment. But, says Douglas, "These are imperfect options because inflammation often recurs when the treatment ends." He is hopeful that rituximab can offer sustained improvement. Douglas observes that the results from a small case series must be viewed with some caution. But given the substantial benefits for patients treated with rituximab, he sees good reason to proceed with a large-scale clinical trial to test this promising new drug.
Source
Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy; Ophthalmology, 2009; Chong et al.; DOI: 10.1016/j.ophtha.2009.05.029
University of Michigan Health System Newsroom
Archive issues: (50)
Archive list: 1 2 3 4 5 6 7 8 9 10 11 12 [13] 14 15 16 17
November 8, 2009 | American Diabetes Association Launches Campaign to "Stop Diabetes"How much do you know about diabetes? Many Americans do not know much about this disease that strikes someone every 20 seconds in the United States. That is one reason why the American Diabetes Association (ADA) has launched its "Stop Diabetes" campaign as part of American Diabetes Month. According to the results of a survey conducted by the American Diabetes Association over the last 18 months, Americans have ...
November 7, 2009 | Strong Immune Response by Healthy Pregnant Women to H1N1 VaccineAn ongoing clinical trial finds that healthy pregnant women have a strong immune response after receiving just one dose of H1N1 influenza vaccine. The trial, which began on September 9, is sponsored by the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health. Both the Centers for Disease Control and Prevention (CDC) and its Advisory Committee on Immunization Practices (ACIP) ...
November 6, 2009 | Salt and diet soda can both take a toll on kidneysResearch from Brigham and Women's Hospital shows that salt and diet soda can take a toll on our kidneys. Consuming a high salt diet and artificially sweetened drinks was linked to greater kidney function declines over an eleven year period. Women participating in the Nurses' Health Study were examined to find the association between diet soda and salt on kidney function decline, and included 3000 ...
Related articles:
Treatment - pain control
Pain control is usually necessary in the IC/PBS treatment plan. The pain of IC/PBS has been rated equivalent to cancer pain and may lead to central sensitization if untreated. Medication. The use of a variety of traditional pain medications, including opiates and synthetic opioids like tramadol, is often necessary to treat the varying degrees of pain. Even children with IC/PBS should be appropriately addressed regarding pelvic ...Section: Interstitial cystitis
Stoicism and emotional repression
Society has different rules with regards to the way that men and women are supposed to express themselves. Men are generally regarded as the ones who are supposed to give comfort and strength. If they break down, cry, or seek comfort they may lose face. Women and other men do not give men an option to express feeling sad, tired, weak, depressed, inadequate, needy, or lonely without ...Section: Mens health risks
Treatment - surgery
Surgical interventions are rarely used for IC/PBS. Surgical intervention is very unpredicatable for IC/PBS, and is considered a treatment of last resort when all other treatment modalities have failed and pain is severe. Some patients who opt for surgical intervention continue to experience pain after surgery. Surgical interventions for IC/PBS include transurethral fulguration and resection of ulcers, using electricity/laser; bladder ...Section: Interstitial cystitis